^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
Excerpt:
Roche...announced that the European Commission has approved Tecentriq® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adults with non-small cell lung cancer (NSCLC) with a high risk of recurrence* whose tumours express PD-L1≥50% and who do not have EGFR mutant or ALK-positive NSCLC.
Source:
Title:
Efficacy and safety of Bladder Preservation Therapy in combination with Atezolizumab and Radiation Therapy (BPT-ART) for invasive bladder cancer: Interim analysis from a multicenter, open-label, prospective phase II trial
Published date:
05/15/2023
Excerpt:
Radiotherapy (41.4 Gy to the small pelvic field and 16.2 Gy to the whole bladder) was given plus 1200 mg intravenous atezolizumab every 3 weeks....High pCR rates were achieved in older patients (90.9%) and in patients with high PD-L1-expressing tumors (95.8% vs. 71.4%).
DOI:
https://doi.org/10.1016/j.ijrobp.2023.05.013
